EGFR INHIBITOR Russian patent published in 2024 - IPC A61K31/519 A61P35/00 C07D487/04 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of a disease associated with EGFR, where R₁ is a C1-C4 alkyl group, optionally having a C1-C4 alkoxy group as a substitute, or a C3-C4 cycloalkyl group; R₂ is a hydrogen atom, a halogen atom, a C1-C6 alkyl group, optionally having from 1 to 5 C1-C4 alkoxy groups or fluorine atoms as substitutes, or a C1-C6 alkoxy group; R₃ is a hydrogen atom or a C1-C4 alkyl group, optionally having from 1 to 5 fluorine atoms as substitutes; R₄ is a hydrogen atom or a C1-C4 alkyl group; and R₅ is a phenyl group optionally having from 1 to 3 substitutes selected from fluorine atoms and chlorine atoms. Invention also relates to a method of treating EGPR-mediated diseases, particularly an EGPR-positive tumor based on the compound of formula (I).

EFFECT: invention provides treating EGPR-mediated diseases and can find application in medicine.

30 cl, 4 dwg, 7 tbl, 19 ex